Cargando…
Tear fluid and complement activation products in tears after ocular surgery
PURPOSE: Due to technological advancements, surgical invasiveness has been reduced. However, cataract surgery has been implicated in causing postoperative inflammation, including dry eye syndrome. The innate immune system may be involved in postoperative inflammation, and complement activation could...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355014/ https://www.ncbi.nlm.nih.gov/pubmed/37464366 http://dx.doi.org/10.1186/s12886-023-03037-6 |
_version_ | 1785075049140584448 |
---|---|
author | Maehara, Hiroki Norikawa, Koki Tanaka, Keiichiro Kato, Yutaka Kasai, Akihito Omori, Tomoko Machida, Takeshi Sekine, Hideharu Sekiryu, Tetsuju |
author_facet | Maehara, Hiroki Norikawa, Koki Tanaka, Keiichiro Kato, Yutaka Kasai, Akihito Omori, Tomoko Machida, Takeshi Sekine, Hideharu Sekiryu, Tetsuju |
author_sort | Maehara, Hiroki |
collection | PubMed |
description | PURPOSE: Due to technological advancements, surgical invasiveness has been reduced. However, cataract surgery has been implicated in causing postoperative inflammation, including dry eye syndrome. The innate immune system may be involved in postoperative inflammation, and complement activation could potentially play a crucial role in defense against pathogens, homeostasis, and wound healing. To investigate changes in the tear film complement activation products (CAPs) and ocular surface after vitrectomy combined with cataract surgery. METHODS: Forty-three patients (23 women; median age, 69 years) were enrolled in this prospective study and underwent phacoemulsification and vitrectomy. We measured Schirmer's test (ST) and CAPs in the tears at baseline (the day before surgery), 4 days and 1 month after the surgery. Tears were collected in microtubes. The CAPs in the tear fluid were analyzed by cytometric bead array. RESULTS: The median ST (8.5 mm) at baseline increased to 16 mm at 4 days ( P < 0.001) and 10 mm at 1 month (P = 0.44). The C3a levels (1202 pg/ml) at baseline increased to 2753 pg/ml at 4 days (P < 0.001), and 1763 pg/ml at 1 month (P = 0.049). The C4a levels (476 pg/ml) at baseline increased to 880 pg/ml at 4 days (P < 0.001), and 657 pg/ml at 1 month (P = 0.013). The C5a levels (22.6 pg/ml) at baseline increased to 470.9 pg/ml at 4 days (P < 0.001), and 38.3 pg/ml at 1 month (P = 0.0048). The surgical eyes were divided into the short ST group (≦ 10 mm, n = 22) and long ST group (> 10 mm, n = 21) based on the preoperative ST values. At 1 month postoperatively, the C3a levels were 2194 pg/ml in the preoperative short ST group and 1391 pg/ml in the long ST group, with significantly higher C3a concentrations in the short ST group (P < 0.001). CONCLUSIONS: The CAPs levels in tears increased after vitrectomy combined with cataract surgery. A preoperative deficit in tear secretion might induce prolonged complement activation and delayed recovery of ocular surface parameters postoperatively. |
format | Online Article Text |
id | pubmed-10355014 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103550142023-07-20 Tear fluid and complement activation products in tears after ocular surgery Maehara, Hiroki Norikawa, Koki Tanaka, Keiichiro Kato, Yutaka Kasai, Akihito Omori, Tomoko Machida, Takeshi Sekine, Hideharu Sekiryu, Tetsuju BMC Ophthalmol Research PURPOSE: Due to technological advancements, surgical invasiveness has been reduced. However, cataract surgery has been implicated in causing postoperative inflammation, including dry eye syndrome. The innate immune system may be involved in postoperative inflammation, and complement activation could potentially play a crucial role in defense against pathogens, homeostasis, and wound healing. To investigate changes in the tear film complement activation products (CAPs) and ocular surface after vitrectomy combined with cataract surgery. METHODS: Forty-three patients (23 women; median age, 69 years) were enrolled in this prospective study and underwent phacoemulsification and vitrectomy. We measured Schirmer's test (ST) and CAPs in the tears at baseline (the day before surgery), 4 days and 1 month after the surgery. Tears were collected in microtubes. The CAPs in the tear fluid were analyzed by cytometric bead array. RESULTS: The median ST (8.5 mm) at baseline increased to 16 mm at 4 days ( P < 0.001) and 10 mm at 1 month (P = 0.44). The C3a levels (1202 pg/ml) at baseline increased to 2753 pg/ml at 4 days (P < 0.001), and 1763 pg/ml at 1 month (P = 0.049). The C4a levels (476 pg/ml) at baseline increased to 880 pg/ml at 4 days (P < 0.001), and 657 pg/ml at 1 month (P = 0.013). The C5a levels (22.6 pg/ml) at baseline increased to 470.9 pg/ml at 4 days (P < 0.001), and 38.3 pg/ml at 1 month (P = 0.0048). The surgical eyes were divided into the short ST group (≦ 10 mm, n = 22) and long ST group (> 10 mm, n = 21) based on the preoperative ST values. At 1 month postoperatively, the C3a levels were 2194 pg/ml in the preoperative short ST group and 1391 pg/ml in the long ST group, with significantly higher C3a concentrations in the short ST group (P < 0.001). CONCLUSIONS: The CAPs levels in tears increased after vitrectomy combined with cataract surgery. A preoperative deficit in tear secretion might induce prolonged complement activation and delayed recovery of ocular surface parameters postoperatively. BioMed Central 2023-07-18 /pmc/articles/PMC10355014/ /pubmed/37464366 http://dx.doi.org/10.1186/s12886-023-03037-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Maehara, Hiroki Norikawa, Koki Tanaka, Keiichiro Kato, Yutaka Kasai, Akihito Omori, Tomoko Machida, Takeshi Sekine, Hideharu Sekiryu, Tetsuju Tear fluid and complement activation products in tears after ocular surgery |
title | Tear fluid and complement activation products in tears after ocular surgery |
title_full | Tear fluid and complement activation products in tears after ocular surgery |
title_fullStr | Tear fluid and complement activation products in tears after ocular surgery |
title_full_unstemmed | Tear fluid and complement activation products in tears after ocular surgery |
title_short | Tear fluid and complement activation products in tears after ocular surgery |
title_sort | tear fluid and complement activation products in tears after ocular surgery |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355014/ https://www.ncbi.nlm.nih.gov/pubmed/37464366 http://dx.doi.org/10.1186/s12886-023-03037-6 |
work_keys_str_mv | AT maeharahiroki tearfluidandcomplementactivationproductsintearsafterocularsurgery AT norikawakoki tearfluidandcomplementactivationproductsintearsafterocularsurgery AT tanakakeiichiro tearfluidandcomplementactivationproductsintearsafterocularsurgery AT katoyutaka tearfluidandcomplementactivationproductsintearsafterocularsurgery AT kasaiakihito tearfluidandcomplementactivationproductsintearsafterocularsurgery AT omoritomoko tearfluidandcomplementactivationproductsintearsafterocularsurgery AT machidatakeshi tearfluidandcomplementactivationproductsintearsafterocularsurgery AT sekinehideharu tearfluidandcomplementactivationproductsintearsafterocularsurgery AT sekiryutetsuju tearfluidandcomplementactivationproductsintearsafterocularsurgery |